156 related articles for article (PubMed ID: 27062254)
1. A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies.
van Beijnum JR; Thijssen VL; Läppchen T; Wong TJ; Verel I; Engbersen M; Schulkens IA; Rossin R; Grüll H; Griffioen AW; Nowak-Sliwinska P
Int J Cancer; 2016 Aug; 139(4):824-35. PubMed ID: 27062254
[TBL] [Abstract][Full Text] [Related]
2. Unraveling galectin-1 as a novel therapeutic target for cancer.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
[TBL] [Abstract][Full Text] [Related]
3. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
Laderach DJ; Gentilini LD; Giribaldi L; Delgado VC; Nugnes L; Croci DO; Al Nakouzi N; Sacca P; Casas G; Mazza O; Shipp MA; Vazquez E; Chauchereau A; Kutok JL; Rodig SJ; Elola MT; Compagno D; Rabinovich GA
Cancer Res; 2013 Jan; 73(1):86-96. PubMed ID: 23108139
[TBL] [Abstract][Full Text] [Related]
4. Role of Galectins in Tumors and in Clinical Immunotherapy.
Chou FC; Chen HY; Kuo CC; Sytwu HK
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859
[TBL] [Abstract][Full Text] [Related]
5. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress.
Ito K; Scott SA; Cutler S; Dong LF; Neuzil J; Blanchard H; Ralph SJ
Angiogenesis; 2011 Sep; 14(3):293-307. PubMed ID: 21523436
[TBL] [Abstract][Full Text] [Related]
6. Lactulose as a novel template for anticancer drug development targeting galectins.
Kishor C; Ross RL; Blanchard H
Chem Biol Drug Des; 2018 Oct; 92(4):1801-1808. PubMed ID: 29888844
[TBL] [Abstract][Full Text] [Related]
7. Galectin-1 and -9 in angiogenesis: a sweet couple.
Thijssen VL; Griffioen AW
Glycobiology; 2014 Oct; 24(10):915-20. PubMed ID: 24861051
[TBL] [Abstract][Full Text] [Related]
8. The Role of Galectin-1 in Cancer Progression, and Synthetic Multivalent Systems for the Study of Galectin-1.
Cousin JM; Cloninger MJ
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649167
[TBL] [Abstract][Full Text] [Related]
9. Regulation of galectins by hypoxia and their relevance in angiogenesis: strategies and methods.
Salatino M; Croci DO; Laderach DJ; Compagno D; Gentilini L; Dalotto-Moreno T; Dergan-Dylon LS; Méndez-Huergo SP; Toscano MA; Cerliani JP; Rabinovich GA
Methods Mol Biol; 2015; 1207():293-304. PubMed ID: 25253148
[TBL] [Abstract][Full Text] [Related]
10. Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis.
Heusschen R; Schulkens IA; van Beijnum J; Griffioen AW; Thijssen VL
Biochim Biophys Acta; 2014 Feb; 1842(2):284-92. PubMed ID: 24333696
[TBL] [Abstract][Full Text] [Related]
11. Galectin-1 inhibitors and their potential therapeutic applications: a patent review.
Blanchard H; Bum-Erdene K; Bohari MH; Yu X
Expert Opin Ther Pat; 2016 May; 26(5):537-54. PubMed ID: 26950805
[TBL] [Abstract][Full Text] [Related]
12. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Rabinovich GA; Bieche I; Vidaud M; de Gramont A; Martinet M; Cvitkovic E; Faivre S; Raymond E
Eur J Cancer; 2014 Sep; 50(14):2463-77. PubMed ID: 25042151
[TBL] [Abstract][Full Text] [Related]
13. Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors.
Stalin J; Nollet M; Garigue P; Fernandez S; Vivancos L; Essaadi A; Muller A; Bachelier R; Foucault-Bertaud A; Fugazza L; Leroyer AS; Bardin N; Guillet B; Dignat-George F; Blot-Chabaud M
Oncogene; 2016 Oct; 35(42):5489-5500. PubMed ID: 27065325
[TBL] [Abstract][Full Text] [Related]
14. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
15. Varied expression and localization of multiple galectins in different cancer cell lines.
Satelli A; Rao PS; Gupta PK; Lockman PR; Srivenugopal KS; Rao US
Oncol Rep; 2008 Mar; 19(3):587-94. PubMed ID: 18288388
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice.
Ran S; He J; Huang X; Soares M; Scothorn D; Thorpe PE
Clin Cancer Res; 2005 Feb; 11(4):1551-62. PubMed ID: 15746060
[TBL] [Abstract][Full Text] [Related]
17. Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.
Paz H; Joo EJ; Chou CH; Fei F; Mayo KH; Abdel-Azim H; Ghazarian H; Groffen J; Heisterkamp N
J Exp Clin Cancer Res; 2018 Mar; 37(1):67. PubMed ID: 29580262
[TBL] [Abstract][Full Text] [Related]
18. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.
Dings RP; Miller MC; Nesmelova I; Astorgues-Xerri L; Kumar N; Serova M; Chen X; Raymond E; Hoye TR; Mayo KH
J Med Chem; 2012 Jun; 55(11):5121-9. PubMed ID: 22575017
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression.
Tang D; Gao J; Wang S; Ye N; Chong Y; Huang Y; Wang J; Li B; Yin W; Wang D
Tumour Biol; 2016 Feb; 37(2):1889-99. PubMed ID: 26323258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
